Edward G. D. Tuddenham

Goodyear (United Kingdom) — United Kingdom

Medicine · Health Sciences

71h-index21.4kcitations393works8.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(208), Blood Coagulation and Thrombosis Mechanisms(144), Platelet Disorders and Treatments(91), Coagulation, Bradykinin, Polyphosphates, and Angioedema(45), Virus-based gene therapy research(41)

Publications393 total

Adeno-associated viral integration profiles in human liver biopsies following Hemophilia A gene therapy
Blood·2025Open Access
Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody
Blood·2025· 3 cited
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B
New England Journal of Medicine·2025· 26 citedOpen Access
The complex, confusing and poorly understood immune responses to <scp>AAV</scp>‐mediated gene transfer in haemophilia—Is more or less immunosuppression required?
Journal of Viral Hepatitis·2024· 3 citedOpen Access
Mathematical models of coagulation—are we there yet?
Journal of Thrombosis and Haemostasis·2024· 10 citedOpen Access
Stable Therapeutic Transgenic FIX Levels for More Than 10 Years in Subjects with Severe Hemophilia B Who Received scAAV2/8-LP1-Hfixco Adeno-Associated Virus Gene Therapy
Blood·2023· 14 cited
GO-8: Stable Expression of Factor VIII over 5 Years Following Adeno-Associated Gene Transfer in Subjects with Hemophilia a Using a Novel Human Factor VIII Variant
Blood·2023· 14 cited
Long-Term Persistence of Antibodies to Adeno-Associated Viral Vectors Following Gene Therapy with scAAV8-LP1-Fixco
Blood·2023· 5 cited
The Use of a Pegylated Liposome in a Phase II Trial to Enhance the Potency and Extend the Dosing Interval of Prophylactic Standard Half-Life FVIII, without Increasing the Dose
Blood·2022
Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII
Blood·2022
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B
New England Journal of Medicine·2022· 145 citedOpen Access
Prophylactic Treatment of Severe Haemophilia Á Patients with Inhibitors to FVIII with Peglip-FVIII
Blood·2021
Haemophilia, the journey in search of a cure. 1960–2020
British Journal of Haematology·2020· 14 citedOpen Access
Factor VIII: the protein, cloning its gene, synthetic factor and now – 35 years later – gene therapy; what happened in between?
British Journal of Haematology·2020· 10 citedOpen Access
LATE-BREAKING AND COVID-19 ORAL COMMUNICATION SESSION ABSTRACTS
2020· 1 cited
Global coagulation assays in hemophilia A: A comparison to conventional assays
Research and Practice in Thrombosis and Haemostasis·2019· 22 citedOpen Access
Interaction Between the a3 Region of Factor VIII and the TIL’E’ Domains of the von Willebrand Factor
Biophysical Journal·2019· 13 citedOpen Access
Enhancing FVIII Expression By Modifying B-Domain Sequence for Hemophilia A Gene Therapy
Blood·2018
Adeno-Associated Mediated Gene Transfer for Hemophilia B:8 Year Follow up and Impact of Removing "Empty Viral Particles" on Safety and Efficacy of Gene Transfer
Blood·2018· 112 cited
GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant
Blood·2018· 56 cited
page 1 of 20Next →

Frequent Co-authors

John H. McVey(8), Amit C. Nathwani(7), Jenny McIntosh(7), Richard M. Lawn(6), Anne Riddell(5), Catherine Y. Ng(5), John T. Gray(5), Andrew M. Davidoff(5), Jane Gitschier(5), Geoffrey Kemball‐Cook(5), R. Schwaab(5), Pratima Chowdary(4), Arthur W. Nienhuis(4), Johannes Oldenburg(4), D.N. Cooper(4), Cecilia Rosales(3), Junfang Zhou(3), Yunyu Spence(3), Christopher L. Morton(3), Katherine A. High(3)